

# Plinest Eye



## Polynucleotides


Plinest Eye is a PN HPT™ based product obtained through **High Purification Technology** featuring a high degree of purification and safety

**Treatment Goal:** Suggested for **improving periorcular skin texture, firmness and elasticity** [1,2,4]

**Composition** [1]: **PN HPT™ 15mg/2ml**, sterile, non-pyrogenic, viscoelastic gel

**Pack** [1]: 1 x 2ml pre-filled syringe

**Needle** [1]: 2 x 30G ½ needle




## SKIN PRIMING: BEYOND THE STANDALONE THERAPY

The **Polynucleotides HPT™ PRIMING** prepares the skin and makes it more receptive to medical aesthetic and anti-ageing treatments. It generates a **synergistic effect with: laser, radiofrequency, fillers, peeling, needling, and surgery** [3]


## CLINICAL EVIDENCE

### An Innovative PN HPT™-based Medical Device for the Therapy of Deteriorated Periorcular Skin Quality [2]

- **Patients:** a real-world cohort of 48 ambulatory outpatients with periorcular skin quality problems
- **Treated Areas:** Eye Contour
- **Treatment protocol and Methods:** 3-sessions intradermal injection cycle with PN HPT™ 15 mg/2ml - based gel in the periorcular district with timepoint evaluation at baseline (T0), 2 to 3 weeks after baseline (T1), and after 2 to 3 further weeks (T2)
- **Assesment:** Wrinkle Severity Rating Scale (WSRS) and Global Aesthetic Improvement Scale (GAIS) at baseline (T0) and four weeks after the last PN HPT™ intradermal injection (T2)
- **Results:** the mean whole-cohort WSRS score improved from  $3.3 \pm 0.93$  at (T0) to  $1.8 \pm 0.90$  (T2) -45.5% including the 39 cohort outpatients with hypotrophic skin -46.9%.
- **Safety:** the treatment cycle with Plinest Eye was well tolerated. A few mild local adverse effects at the injection sites due to the delicate skin areas, as the periorcular district, disappeared spontaneously in a few hours



**Figure 1a:** Comparison of the mean WSRS scores for periorcular and facial wrinkles and skin quality at the baseline and the final follow-up visits for all cohort subjects and outpatients



**Figure 1b:** Comparison of the mean WSRS scores for periorcular and facial wrinkles and skin quality between the baseline and the final follow-up visits for the 39 cohort outpatients with hypotrophic skin


PN HPT™ retain the usual excellent value and safety in improving skin quality in the periorcular region

## Treatment protocols and injection techniques

### YOUNGER AND AGING SKIN BIO-REGENERATION

- Micro-droplet technique with injection spaced out by 0.5 to 1cm or linear retrograde technique [3]
- 1-2ml per session  
One session every 14 or 21 days for a total of 3-4 sessions [3]

- **Areas of treatment:** Eye contour [2]
- **Depth of injection:** Intradermal [1]



**Figure 2:**  
ANTERA 3D objective and photographs evaluations of a female subject before treatment (left) and after 30 days (right) of follow-up with PN HPT™ 15mg/2ml [4]

Photographs are owned by the authors and belongs to Mastelli clinical data base

For professional use only - COD: C-MD013FSENG0124

**Bibliography: 1)** Plinest Eye IFU (Instruction for use) | **2)** Palmieri IP, Moro L, Fraone N, et al. An innovative PN-HPT™-based Medical Device for the Therapy of Deteriorated Periocular Skin Quality. *Surgical Research*. 2023; 5(2):1-7. | **3)** Cavallini M, Bartoletti E, Maioli L, Massirone A, Palmieri IP, Papagni M, Priori M, Trocchi G, members of The Polynucleotides HPT™ Priming Board, Collegio Italiano delle Società Scientifiche di Medicina Estetica (Italian College of the Aesthetic Medicine Scientific Societies) - SIME, AGORÀ, SIES. Consensus Report on the Use of PN-HPT™ (Polynucleotides Highly Purified Technology) in Aesthetic Medicine. *Journal of Cosmetic Dermatology* 2020; 1-7. | **4)** Cavallini M, Papagni M. *Aesthetic & Anti-Aging Medicine World Congress, Monte Carlo 2018*